



State of California—Health and Human Services Agency  
California Department of Public Health



KAREN L. SMITH, MD, MPH  
Director & State Health Officer

EDMUND G. BROWN JR.  
Governor

OFFICE OF AIDS (OA)  
AIDS Drug Assistance Program (ADAP)

Management Memorandum  
Memorandum Number: 2016-16

Date: August 26, 2016

TO: LOCAL ADAP COORDINATORS  
ADAP ENROLLMENT WORKERS

SUBJECT: ADDITION OF ELBASVIR/GRAZOPREVIR (ZEPATIER™) TO THE ADAP  
FORMULARY

**Effective August 16, 2016**, elbasvir 50 mg/grazoprevir 100 mg (Zepatier™), has been added to the ADAP formulary. This new fix-dose combination drug received federal Food and Drug Administration approval on January 28, 2016 for treatment of hepatitis C (HCV) infected patients with genotypes 1 or 4.

With the addition of elbasvir/grazoprevir, the ADAP formulary consists of approximately 200 drugs, including those necessary to treat HIV in accordance with the federal treatment guidelines for HIV/AIDS and associated opportunistic infections.

If you have any questions regarding the addition of this drug to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Niki Dhillon, Chief  
ADAP Branch  
Office of AIDS